| Angiotensin-II-induced expression of proto-oncogene (c-fos, jun-B and c-jun) mRNA in bovine adrenocortical fasciculata cells (BAC) is mediated by AT-1 receptors. | adrenocortical, |
| The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. | lymphoma, |
| The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. | lymphoma, |
| Jun-B oncogene aberrations in cervical cancer cell lines. | cervical, |
| transgenic mice that expressed JunB under the control of the ubiquitin C promoter were partially protected from the transforming potential of the Abelson oncogene. However, transformed B cells eventually escaped from the inhibitory effect of JunB. | None |
| C-jun and jun-B oncogene expression during placental development. | None |
| Growth hormone induces expression of c-jun and jun B oncogenes and employs a protein kinase C signal transduction pathway for the induction of c-fos oncogene expression. | None |
| Different members of the jun proto-oncogene family exhibit distinct patterns of expression in response to type beta transforming growth factor. | None |
| Chromosomal localization of the three members of the jun proto-oncogene family in mouse and man. | None |
| findings uncover the oncogenic role of the JUNB/CD30 axis and its potential as therapeutic target in ALK+ ALCL. | None |
| Differential induction and regulation of c-jun, junB, junD and c-fos by human papillomavirus type 11 E5a oncoprotein. | None |
| Elevated expression of the junB proto-oncogene is essential for v-fos induced transformation of Rat-1 cells. | None |
| The regulation mechanism of c-jun and junB by human papillomavirus type 16 E5 oncoprotein. | None |
| Development of competitive mRNA PCR for the quantification of interleukin-6-responsive junB oncogene expression. | None |
| EGF promotes development of a differentiated trophoblast phenotype having c-myc and junB proto-oncogene activation. | None |